Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Park SI, et al. Blood. 2010 Nov 18;116(20):4231-9. doi: 10.1182/blood-2010-05-282327. Epub 2010 Aug 11. Blood. 2010. PMID: 20702781 Free PMC article.
A pretargeted nanoparticle system for tumor cell labeling.
Gunn J, Park SI, Veiseh O, Press OW, Zhang M. Gunn J, et al. Among authors: park si. Mol Biosyst. 2011 Mar;7(3):742-8. doi: 10.1039/c005154c. Epub 2010 Nov 24. Mol Biosyst. 2011. PMID: 21107453 Free PMC article.
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Pagel JM, et al. Among authors: park si. Blood. 2011 Jul 21;118(3):703-11. doi: 10.1182/blood-2011-04-347039. Epub 2011 May 25. Blood. 2011. PMID: 21613259 Free PMC article.
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, Stayton PS, Orgun N, Hylarides M, Buchegger F, Kenoyer AL, Axtman A, Gopal AK, Green DJ, Pagel JM, Press OW. Park SI, et al. Clin Cancer Res. 2011 Dec 1;17(23):7373-82. doi: 10.1158/1078-0432.CCR-11-1204. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976541 Free PMC article.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Merryman RW, et al. Blood Adv. 2021 Mar 23;5(6):1648-1659. doi: 10.1182/bloodadvances.2020003556. Blood Adv. 2021. PMID: 33710337 Free PMC article.
1,318 results